Catalyst Dossier · compiled by CeliA 🧫

UroGen Pharma Ltd. (URGN)

Pharmaceutical Preparations · market cap $1.6B · as of 2026-07-02

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

UroGen Pharma (URGN) is a ~$1.8B market cap specialty pharma focused on uro-oncology, with a commercial-stage business generating ~$110M in 2025 revenue and a pipeline spanning four Phase 3 assets. The company carries $90M net debt, roughly 7.3 months of cash runway, and has posted widening net losses every year since 2021, raising near-term financing risk despite revenue growth.

The catalyst path

2026-08-06Earningsimp 5/10
2027-03-15 (est.)Phase 3 · UGN-104imp 9/10

Pipeline

Asset	Phase	Indication
120 mg MMC in 90ml gel	Phase 2	Bladder Cancer
UGN-101 instillations	Phase 3	Carcinoma, Transitional Cell
UGN-102	Phase 3	Bladder Cancer
UGN-104	Phase 3	Upper Urinary Tract Urothelial Carcinoma
UGN-103	Phase 3	Bladder Cancer

Price & technical context

3-month

+100.7%

6-month

+64.1%

12-month

+193.4%

52-wk range

$13.49–$38.02

vs 50-day MA

+29.9%

vs 200-day MA

+66.4%

Realized vol

66.1%

Max drawdown

-79.5%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for URGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.